{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:45:23Z","timestamp":1773153923652,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.urolonc.2025.08.031","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:01:33Z","timestamp":1760587293000},"page":"63.e1-63.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort"],"prefix":"10.1016","volume":"44","author":[{"given":"Jin-Liern","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvan","family":"Cristescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Markensohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2025.08.031_bib0001","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006098","article-title":"Signal transduction in cancer","volume":"5","author":"Sever","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.031_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.urolonc.2025.08.031_bib0003","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-17-1701","article-title":"Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer","volume":"77","author":"Goldstein","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.031_bib0005","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ctrv.2016.09.018","article-title":"Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: new direction and new hope","volume":"50","author":"Morales-Barrera","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"10.1016\/j.urolonc.2025.08.031_bib0007","doi-asserted-by":"crossref","first-page":"16234","DOI":"10.18632\/oncotarget.24611","article-title":"Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer","volume":"9","author":"Tanaka","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12672-024-01173-z","article-title":"The roles of FGFR3 and c-MYC in urothelial bladder cancer","volume":"15","author":"Bogale","year":"2024","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in cancer: from the bench to the bedside","volume":"41","author":"Gandullo-S\u00e1nchez","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0010","article-title":"GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma","volume":"39","author":"Guan","year":"2024","journal-title":"Biochem Biophys Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.031_bib0011","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.urolonc.2025.08.031_bib0013","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","article-title":"KRAS as a therapeutic target","volume":"21","author":"McCormick","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.031_bib0014","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3892\/or.2016.5297","article-title":"The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (Review)","volume":"37","author":"Miekus","year":"2017","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"issue":"7492","key":"10.1016\/j.urolonc.2025.08.031_bib0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.031_bib0019","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2025.08.031_bib0021","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"issue":"12","key":"10.1016\/j.urolonc.2025.08.031_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11934-018-0853-5","article-title":"Molecular characterization of bladder cancer","volume":"19","author":"Chandrasekar","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.031_bib0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"suppl 4","key":"10.1016\/j.urolonc.2025.08.031_bib0024","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2024.42.4_suppl.574","article-title":"HER2 mutation and bladder cancer (BC): prevalence and clinical outcomes","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7855","key":"10.1016\/j.urolonc.2025.08.031_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0026","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.urolonc.2025.08.031_bib0027","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0028","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/EDBK_155880","article-title":"Transforming clinical trial eligibility criteria to reflect practical clinical application","volume":"35","author":"Kim","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.urolonc.2025.08.031_bib0029","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","article-title":"AACR Project GENIE: 100,000 cases and beyond","volume":"12","author":"Pugh","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00083","article-title":"American Association for Cancer Research project Genomics Evidence Neoplasia Information Exchange: from inception to first data release and beyond-lessons learned and member institutions\u2019 perspectives","volume":"2","author":"Micheel","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"issue":"8","key":"10.1016\/j.urolonc.2025.08.031_bib0031","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0032","unstructured":"American Association for Cancer ResearchAACR Project GENIE: Biopharma Collaborativ eAccessed January 16, 2025. https:\/\/www.aacr.org\/professionals\/research\/aacr-project-genie\/bpc\/2019."},{"issue":"23","key":"10.1016\/j.urolonc.2025.08.031_bib0033","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0034","article-title":"A scalable quality assurance process for curating oncology electronic health records: the Project GENIE Biopharma Collaborative approach","volume":"6","author":"Lavery","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0035","article-title":"Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC)","volume":"7","author":"Acebedo","year":"2025","journal-title":"ESMO Real World Data Digital Oncol"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0036","series-title":"AJCC cancer staging manual","year":"2010"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41588-024-02030-z","article-title":"Comprehensive genomic characterization of early-stage bladder cancer","volume":"57","author":"Prip","year":"2025","journal-title":"Nat Genet"},{"issue":"suppl 16","key":"10.1016\/j.urolonc.2025.08.031_bib0038","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2023.41.16_suppl.4511","article-title":"Fibroblast growth factor receptor3 (FGFR3) alterations in PROOF 302: a phase III trial of infigratinib (BGJ398)as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)","volume":"41","author":"Grivas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.031_bib0039","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"10.1016\/j.urolonc.2025.08.031_bib0040","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"D1","key":"10.1016\/j.urolonc.2025.08.031_bib0041","doi-asserted-by":"crossref","first-page":"D1334","DOI":"10.1093\/nar\/gkab970","article-title":"OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer","volume":"50","author":"Tang","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.590618","article-title":"A TP53-associated immune prognostic signature for the prediction of overall survival and therapeutic responses in muscle-invasive bladder cancer","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0043","doi-asserted-by":"crossref","first-page":"e8261","DOI":"10.7717\/peerj.8261","article-title":"Significance of TP53 mutation in bladder cancer disease progression and drug selection","volume":"7","author":"Wu","year":"2019","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0044","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820976665","article-title":"Alterations in TP53 are a potential biomarker of bladder cancer patients who benefit from immune checkpoint inhibition","volume":"27","author":"Lyu","year":"2020","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.031_bib0045","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1200\/JCO.1995.13.6.1384","article-title":"Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC","volume":"13","author":"Sarkis","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.08.031_bib0046","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0048","series-title":"(erdafitinib) tablets, for oral use. 04\/2020","year":"2024"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0050","unstructured":"National Library of Medicine. Disitamabvedotin with pembrolizumab vs chemotherapy in previously untreated urothelial cancer expressing HER2. September 12, 2025.https:\/\/clinicaltrials.gov\/study\/NCT05911295?cond=bladder%20cancer%20%2B%20ERBB2&page=4&rank=38. Accessed September 13, 2025."},{"key":"10.1016\/j.urolonc.2025.08.031_bib0053","unstructured":"National Library of Medicine. A phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express fibroblast growth factor receptor (FGFR) gene alterations. May 21, 2025.https:\/\/www.clinicaltrials.gov\/study\/NCT06511648?intr=ERDAFITINIB&aggFilters=studyType:int&viewType=Table&rank=8. Accessed August 21, 2025."},{"key":"10.1016\/j.urolonc.2025.08.031_bib0054","unstructured":"National Library of Medicine. Phase Ib trial of erdafitinib combined with enfortumab vedotin following platinum and PD1\/L1 inhibitors for metastatic urothelial carcinoma with FGFR2\/3 genetic alterations. September 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04963153. Accessed September 18, 2025."},{"issue":"11","key":"10.1016\/j.urolonc.2025.08.031_bib0055","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.3390\/cancers12113413","article-title":"Mutant kras as a biomarker plays a favorable role in FL118-induced apoptosis, reactive oxygen species (ROS) production and modulation of survivin, Mcl-1 and XIAP in human bladder cancer","volume":"12","author":"Santha","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.urolonc.2025.08.031_bib0056","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.62347\/XEBR7848","article-title":"Sotorasib inhibits ubiquitination degradation of TXNIP and suppresses glucose metabolism in KRAS(G12C) mutant bladder cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.031_bib0059","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ctrv.2013.09.001","article-title":"HER2 testing: current status and future directions","volume":"40","author":"Perez","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.031_bib0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.22.00405","article-title":"A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma","volume":"41","author":"Crabb","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.08.031_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fepid.2024.1386922","article-title":"Pitfalls in time-to-event analysis of registry data: a tutorial based on simulated and real cases","volume":"4","author":"Alligon","year":"2024","journal-title":"Front Epidemiol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.08.031_bib0062","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/0008-5472.CAN-22-1274","article-title":"Challenges to using big data in cancer","volume":"83","author":"Sweeney","year":"2023","journal-title":"Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:54:06Z","timestamp":1773096846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1078143925003539"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.031","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}